Patent foramen ovale and cryptogenic stroke: To close or not to close? Closure: What else!

Circulation

Volumn 118, Issue 19, 2008, Pages 1989-1997

  Windecker, Stephan ^a   Meier, Bernhard ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CASE REPORT; CRYPTOGENIC STROKE; DISEASE ASSOCIATION; FEMALE; HEART ANEURYSM; HUMAN; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; STROKE; SYMPTOMATOLOGY; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR;

FORAMEN OVALE, PATENT; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 57149126079     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.757013     Document Type: Review

References (71)

1. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004;126: 483S-512S.
2. Messe SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G, Kasner SE. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Sub-committee of the American Academy of Neurology. Neurology. 2004: 62:1042-1050.
3. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thorn T, Wilson M, Hong Y. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-e146.
4. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390.
5. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
6. Wahl A, Windecker S, Meier B. Evaluation and treatment of abnormalities of the interatrial septum. Catheter Cardiovasc Interv. 2004;63: 94-103.
7. Loscalzo J. Paradoxical embolism: clinical presentation, diagnostic strategies, and therapeutic options. Am Heart J. 1986;112:141-145.
8. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148-1152.
9. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, Glasgow GL. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11-12.
10. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357: 2262-2268.
11. Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86:1902-1908.
12. Mas JL, Zuber M; French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am Heart J. 1995;130: 1083-1088.
13. Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation. 2003; 107:5-9.
14. Kizer JR, Devereux RB. Clinical practice: patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353:2361-2372.
15. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
16. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359:248-252.
17. Petty GW, Khandheria BK, Meissner I, Whisnant JP, Rocca WA, Christianson TJ, Sicks JD, O'Fallon WM, McClelland RL, Wiebers DO. Population-based study of the relationship between patent foramen ovale and cerebrovascular ischemic events. Mayo Clin Proc. 2006;81:602-608.
18. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002; 105:2625-2631.
19. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172-1179.
20. Egred M, Patel JC, Walton S. Impending paradoxical embolism. Circulation. 2001;103:E113-E114.
21. Kessel-Schaefer A, Lefkovits M, Zellweger MJ, Brett W, Ruter F, Pfisterer ME, Buser P. Migrating thrombus trapped in a patent foramen ovale. Circulation. 2001;103:1928.
22. Chan FP, Jones TR. Images in clinical medicine. Paradoxical embolus. N Engl J Med. 2001;345:803.
23. Dorr M, Hummel A. Images in clinical medicine: paradoxical embolism: thrombus in a patent foramen ovale. N Engl J Med. 2007;357:2285.
24. Agmon Y, Khandheira BK, Meissner I, Gentile F, Whisnant JP, Sicks JD, O'Fallon M, Covalt JL, Wiebers DO, Seward JB. Frequency of atrial seplal aneurysms in patients with cerebral ischemic events. Circulation. 1999;99:1942-1944.
25. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm. or both. N Engl J Med. 2001;345:1740-1746.
26. Isayev Y, Chan RK, Pullicino PM. "Economy class" stroke syndrome? Neurology. 2002;58:960-961.
27. Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation. 1998;97: 1946-1951.
28. Cramer SC, Rordorf G, Maki JH, Kramer LA, Grotta JC, Burgin WS, Hinchey JA, Benesch C, Furie KL, Lutsep HL, Kelly E, Longstreth WT Jr. Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study. Stroke. 2004;35:46-50.
29. Khairy P, Landzberg MJ, Gatzoulis MA, Mercier LA, Fernandes SM, Cote JM, Lavoie JP, Fournier A, Guerra PG, Frogoudaki A, Walsh EP, Dore A. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation. 2006; 113:2391-2397.
30. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370: 1773-1779.
31. Steiner MM, Di Tullio MR, Rundek T, Can R, Chen X, Liguori C, Brainin M, Homma S, Sacco RL. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke. 1998;29:944-948.
32. Schuchlenz HW, Weihs W, Horner S, Quehenberger F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med. 2000;109:456-462.
33. Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li Mandri G, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study. Stroke. 1994; 25:582-586.
34. De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, Beccia M, Colonnese C, Fedele F, Fieschi C, Pandian NG. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000;31:2407-2413.
35. Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, Meier B. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation. 2000;101:893-898.
36. Schwerzmann M, Windecker S, Wahl A, Mehta H, Nedeltchev K, Mattle H, Seiler C, Meier B. Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart. 2004;90:186-190.
37. Schuchlenz HW, Saurer G, Weihs W. Patent foramen ovale, atrial septal aneurysm, and recurrent stroke. N Engl J Med. 2002;346:1331-1332; discussion 1331-1332.
38. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112:1063-1072.
39. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992; 117: 461-465.
40. Mohr JP, Homma S. Patent cardiac foramen ovale: stroke risk and closure. Ann Intern Med. 2003;139:787-788.
41. Hausmann D, Mugge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol. 1995;26: 1030-1038.
42. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Meile G; Lausanne Stroke with Paradoxical Embolism Study Group. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Neurology. 1996;46:I301-1305.
43. Cujec B, Mainra R, Johnson DH. Prevention of recurrent cerebral ischemie events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol. 1999; 15:57-64.
44. Nedeltchev K, Arnold M, Wahl A, Sturzenegger M, Vella EE, Windecker S, Meier B, Mattle HP. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry. 2002;72:347-350.
45. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemie stroke. N Engl J Med. 2001;345:1444-1451.
46. Wahl A, Praz F, Stirnimann J, Windecker S, Seiler C, Nedeltchev K, Mattle H, Meier B. Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. Swiss Med Wkly. 2008; 138:567-572.
47. Mattle HP, Meier B, Windecker S. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:2198-2199; author reply 2198-2199.
48. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
49. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
50. Wöhrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet. 2006;368:350-352.
51. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003;139:753-760.
52. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, Sievert H. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43:302-309.
53. Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol. 2005;45:1213-1218.
54. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler. Stroke. 2004;35:2140-2144.
55. Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv. 2006;68: 136-142; discussion 143-144.
56. Alaeddini J, Feghali G, Jenkins S, Ramee S, White C, Abi-Samra F. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J Invasive Cardiol. 2006;18:365-368.
57. Burow A, Schwerzmann M, Wallmann D, Tanner H, Sakata T, Windecker S, Meier B, Delacretaz E. Atrial fibrillation following device closure of patent foramen ovale. Cardiology. 2008;111:47-50.
58. Schoen SP, Boscheri A, Lange SA, Braun MU, Fuhrmann JF, Kappert U, Strasser RH. Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale. Heart. 2007;94:844-847.
59. Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxic embolism. Am J Cardiol. 1996;78:233-236.
60. Hung J, Landzberg MJ, Jenkins KJ, King ME, Lock JE, Palacios IF, Lang P. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol. 2000;35:1311-1316.
61. Wahl A, Meier B, Haxel B, Nedeltchev K, Arnold M, Eicher E, Sturzenegger M, Seiler C, Mattle HP, Windecker S. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology. 2001;57:1330-1332.
62. Beitzke A, Schuchlenz H, Gamillscheg A, Stein JI, Wendelin G. Catheter closure of the persistent foramen ovale: mid-term results in 162 patients. J Interv Cardiol. 2001;14:223-229.
63. Martin F, Sanchez PL, Doherty E, Colon-Hernandez PJ, Delgado G, Inglessis I, Scott N, Hung J, King ME, Buonanno F, Demirjian Z, de Moor M, Palacios IF. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002; 106:1121-1126.
64. Braun MU, Fassbender D, Schoen SP, Haass M, Schraeder R, Scholtz W, Strasser RH. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia, J Am Coll Cardiol. 2002;39:2019-2025.
65. Bruch L, Parsi A, Grad MO, Rux S, Burmeister T, Krebs H, Kleber FX. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation. 2002;105:2845-2848.
66. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, Mattle HP, Meier B. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750-758.
67. Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101:77-82.
68. Chatterjee T, Petzsch M, Ince H, Rehders TC, Korber T, Weber F, Schneider H, Auf der Maur C, Nienaber CA. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol. 2005;18:173-179.
69. Fischer D, Fuchs M, Schaefer A, Schieffer B, Jategaonkar S, Hornig B, Drexler H, Meyer GP. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: procedural and follow-up results after implantation of the Starflex((R)) occluder device with conjunctive intensified anticoagulation regimen. J Interv Cardiol. 2008;21:183-189.
70. Wahl A, Tai T, Praz F, Schwerzmann M, Seiler C, Nedeltchev K, Windecker S, Mattle H, Meier B. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the Amplatzer PFO occluder without intra-procedural echocardiography: effect of device size. J Am Coll Cardiol Interv. In press.
71. Wahl A, Krumsdorf U, Meier B, Sievert H, Ostermayer S, Billinger K, Schwerzmann M, Becker U, Seiler C, Arnold M, Mattle HP, Windecker S. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol. 2005;45:377-380.